Close
Description
Cell and gene therapy have emerged as two of the most significant therapeutic modalities of the 21st century. Both independently and in combination (genetically modified cells), these technologies are starting to produce transformative therapies for patients across a broad range of medical fields including cancer immunotherapy and regenerative medicine. The need for scalable cost-effective manufacturing is a key requirement for the field. The content will include: Stem cells - Sourcing, characterisation and banking Stem cell expansion and differentiation The need for tightly controlled processes Characterisation with respect to stem cell bioprocessing Automation of stem cell bioprocessing Contract manufacture and stem cells Cell Therapies * Embryonic cells * Fetal and adult stem cells * Adult cells Tissue engineering Regulatory and economic challenges Ethics with respect to stem cell bioprocessing and commercialisation Case Studies: Stem cell-based therapies - scale up (allogeneic) and scale out (autologous). In particular the challenge of going from the lab-based discovery techniques into mass production to meet the demands of routine clinical practice
Upon completion of the course, a student should be able to:
- Develop an understanding and working knowledge of manual cell handling, including those that are typically used at research scale and manufacturing scale.
- Develop an understanding and working knowledge of typical technology platforms and unit operations used in cell and gene therapy manufacturing pathways.
- Develop an understanding of how advanced therapies can be characterised and manufactured, including the use of automation technologies and bioanalytics.
Module deliveries for 2024/25 academic year
Last updated
This module description was last updated on 8th April 2024.
听